| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
|
2
|
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
|
Blood
|
2008
|
5.49
|
|
3
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
4
|
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
|
J Clin Oncol
|
2012
|
5.08
|
|
5
|
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
|
Proc Natl Acad Sci U S A
|
2009
|
4.98
|
|
6
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
|
7
|
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
|
Cancer Cell
|
2012
|
4.41
|
|
8
|
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
4.35
|
|
9
|
Biology, risk stratification, and therapy of pediatric acute leukemias: an update.
|
J Clin Oncol
|
2011
|
4.34
|
|
10
|
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
|
J Clin Oncol
|
2009
|
4.20
|
|
11
|
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.
|
Blood
|
2010
|
4.00
|
|
12
|
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
|
Blood
|
2006
|
3.91
|
|
13
|
Germline genomic variants associated with childhood acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
3.71
|
|
14
|
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
|
Blood
|
2010
|
3.66
|
|
15
|
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
3.40
|
|
16
|
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
|
Blood
|
2009
|
2.86
|
|
17
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
|
18
|
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected].
|
J Clin Oncol
|
2008
|
2.51
|
|
19
|
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
2.38
|
|
20
|
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2012
|
2.09
|
|
21
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
|
22
|
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
|
J Clin Oncol
|
2008
|
1.83
|
|
23
|
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
|
J Natl Cancer Inst
|
2013
|
1.81
|
|
24
|
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
|
Nat Med
|
2013
|
1.79
|
|
25
|
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.79
|
|
26
|
Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling.
|
Blood
|
2011
|
1.79
|
|
27
|
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
|
J Clin Oncol
|
2008
|
1.75
|
|
28
|
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2006
|
1.74
|
|
29
|
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.
|
Blood
|
2011
|
1.67
|
|
30
|
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.67
|
|
31
|
Race and outcome in childhood acute lymphoblastic leukemia.
|
JAMA
|
2003
|
1.65
|
|
32
|
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
|
J Clin Oncol
|
2010
|
1.62
|
|
33
|
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group.
|
J Clin Oncol
|
2012
|
1.52
|
|
34
|
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
|
Blood
|
2012
|
1.47
|
|
35
|
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
|
Nat Genet
|
2013
|
1.45
|
|
36
|
Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research.
|
Blood
|
2006
|
1.44
|
|
37
|
End points to establish the efficacy of new agents in the treatment of acute leukemia.
|
Blood
|
2006
|
1.43
|
|
38
|
Obesity and outcome in pediatric acute lymphoblastic leukemia.
|
J Clin Oncol
|
2007
|
1.40
|
|
39
|
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
1.39
|
|
40
|
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
1.39
|
|
41
|
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
|
Pediatr Blood Cancer
|
2011
|
1.33
|
|
42
|
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2012
|
1.29
|
|
43
|
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2011
|
1.25
|
|
44
|
Biology and treatment of acute lymphoblastic leukemia.
|
Pediatr Clin North Am
|
2008
|
1.22
|
|
45
|
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
|
Blood
|
2012
|
1.20
|
|
46
|
Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2012
|
1.20
|
|
47
|
Identification of gene expression profiles that segregate patients with childhood leukemia.
|
Clin Cancer Res
|
2002
|
1.16
|
|
48
|
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2013
|
1.15
|
|
49
|
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
|
Blood
|
2014
|
1.14
|
|
50
|
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.12
|
|
51
|
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
|
J Clin Oncol
|
2013
|
1.07
|
|
52
|
Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
|
Pediatr Blood Cancer
|
2006
|
1.06
|
|
53
|
Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.00
|
|
54
|
Childhood leukemia--new advances and challenges.
|
N Engl J Med
|
2004
|
0.96
|
|
55
|
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
|
Blood
|
2013
|
0.95
|
|
56
|
Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada.
|
Environ Health Perspect
|
2007
|
0.94
|
|
57
|
Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.
|
Pediatr Blood Cancer
|
2012
|
0.93
|
|
58
|
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.
|
Blood
|
2012
|
0.92
|
|
59
|
Identification of genes that are regulated transcriptionally by Myc in childhood tumors.
|
Cancer
|
2003
|
0.92
|
|
60
|
A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Cancer
|
2014
|
0.92
|
|
61
|
Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.
|
J Biol Chem
|
2014
|
0.91
|
|
62
|
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
|
J Pediatr Hematol Oncol
|
2014
|
0.89
|
|
63
|
The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.
|
Am J Pathol
|
2002
|
0.86
|
|
64
|
Biology and treatment of acute lymphoblastic leukemia.
|
Hematol Oncol Clin North Am
|
2010
|
0.86
|
|
65
|
Novel targeted drug therapies for the treatment of childhood acute leukemia.
|
Expert Rev Hematol
|
2009
|
0.85
|
|
66
|
The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
|
J Pediatr Hematol Oncol
|
2014
|
0.85
|
|
67
|
Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines.
|
Apoptosis
|
2006
|
0.85
|
|
68
|
HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia.
|
Leuk Lymphoma
|
2013
|
0.84
|
|
69
|
Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
|
Pediatr Blood Cancer
|
2014
|
0.83
|
|
70
|
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
|
Pediatr Blood Cancer
|
2010
|
0.82
|
|
71
|
Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: when do we say enough?
|
Pediatr Blood Cancer
|
2005
|
0.81
|
|
72
|
Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2.
|
Cancer
|
2004
|
0.81
|
|
73
|
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).
|
Pediatr Blood Cancer
|
2014
|
0.80
|
|
74
|
Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.
|
Paediatr Drugs
|
2007
|
0.80
|
|
75
|
Refining prognosis in BCR-ABL1-positive ALL.
|
Blood
|
2014
|
0.79
|
|
76
|
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2014
|
0.78
|
|
77
|
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
|
Br J Haematol
|
2012
|
0.77
|
|
78
|
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
79
|
Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
80
|
Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
|
Expert Rev Hematol
|
2013
|
0.75
|
|
81
|
Eliminating a gold standard in childhood acute lymphoblastic leukemia?
|
Pediatr Blood Cancer
|
2006
|
0.75
|